key: cord-0866640-tah5l34m
authors: Asghar, Muhammad Sohaib; Yasmin, Farah; Dapke, Kartik; Phadke, Rachana; Shah, Syed Muhammad Ismail; Bin Zafar, Muhammad Daim
title: Derangements of biochemical markers and thyroid function analysis among COVID‐19‐positive patients: A developing country single‐center experience
date: 2021-07-08
journal: J Med Virol
DOI: 10.1002/jmv.27174
sha: 863ee154fd94effaeda4417c9122dcf81d765e91
doc_id: 866640
cord_uid: tah5l34m

The novel virus has a predilection for multi-organ involvement in addition to the respiratory manifestations. It also affects the endocrine system due to the close interplay between immunological and endocrine responses at multiple levels. The activation of inflammatory mediators and immune-mediated glandular damage via the formation of antibodies or cell-mediated damage to the thyroid gland resulting in subacute thyroiditis has also been reported in COVID-19 positive patients. We aimed to explore derangements of biochemical markers and thyroid function tests among patients suffering from COVID-19 infection at our center via a retrospective study conducted on 54 patients with no previous history of thyroid disease. They had a mean age of 53.29 ± 15.59 years, with the majority of them being females (61%). There was a major difference in serum TSH observed among severe/critical COVID-19 patients (p<0.001). Free T3 and T4 levels in the blood were not found to be linked with disease severity. Low serum TSH (<0.996 uIU/mL) was found to be statistically significant with disease severity, Cox proportional hazard model showed a significantly higher risk of disease severity with low TSH levels [HR: 3.303 (95% CI, 1.124-9.705); p=0.03]. The receiver operating characteristic analysis, at a TSH cut-off value of <0.996 uIU/mL, exhibited a sensitivity of 85.7% and specificity of 72.7%, indicating disease severity (AUC=0.779; p=0.001). Patients with low TSH levels (<0.996 uIU/mL) demonstrated significantly low survival time on Kaplan Meier curve while the population with sufficient TSH (>0.996 uIU/mL) had a higher cumulative survival proportion. (Chi-square: 12.650, p<0.001). This article is protected by copyright. All rights reserved.

The novel virus has a predilection for multiorgan involvement in addition to the respiratory manifestations due to the widespread presence of angiotensin-converting enzyme 2 (ACE-2) receptors. The virus also affects the endocrine system due to the close interplay between immunological and endocrine responses at multiple levels. 2 The thyroid gland expresses the ACE-2 receptor, which is necessary for the virus to dock and enter the cell. It also has a possible role in viral replication inside the cell. The activation of inflammatory mediators and immune-mediated glandular damage via the formation of antibodies or cell-mediated damage to the thyroid gland resulting in subacute thyroiditis has also been reported in COVID-19-positive patients. 2 Furthermore, thyroid hormone dysfunction has also been linked to increased mortality in critically ill patients with acute respiratory distress syndrome, which is a leading complication in COVID-19. 3 Although there are postulates contemplating hypothalamic-pituitary-adrenal axis disruption or pituitary dysfunction as a sequela to the SARS-CoV-2 infection, the role of the thyroid hormone is critical in assessing the outcome of critically ill individuals. Hence, we aimed to explore derangements of biochemical markers and thyroid function tests among patients suffering from COVID-19 infection.

A retrospective study was conducted at our center in which patients infected with COVID-19 were evaluated for thyroid hormones. The diagnosis of COVID-19 was reached via either nasopharyngeal or oropharyngeal swab for polymerase chain reaction. The diagnostic kit utilized the principle of real-time fluorescence (RT-PCR), USA-WA1/2020 stock concentration 2.8E + 05 TCID50/ml, with a lower detection limit of 0.003 TCID50/ml. Fifty-four patients with no previous history of thyroid disease were considered and categorized into severity groups based on CDC criteria for disease severity and prognosis; which included mild-moderate (mild respiratory symptoms and fever, on an average 5-6 days after infection), severe disease (dyspnea, respiratory frequency ≥30/min, blood oxygen saturation ≤93%, and/or lung infiltrates >50% of the lung field within 24-48 h) and critical (respiratory failure, septic shock, and/or multiple organ dysfunction/failure). All patients had laboratoryconfirmed COVID-19, age more than 18 years without a history of thyroid disease, and their thyroid function tests were taken during the hospital stay. The thyroid hormones were measured usually within the first 24 h of admission. A total of 3-5 cc of clotted blood or serum was taken for thyroid hormone analysis via Elecsys® E411 Assay (Roche Diagnostics) utilizing chemiluminescence immunoassay. The pediatric population and pregnant females were excluded from the analysis. The reference values of our laboratory for thyroid hormones were as follows: free serum T3: 1.9-5.1 pg/ml; free serum T4: 0.9-1.7 ng/dl; and serum TSH: 0.4-4.2 uIU/ml for 21-54 years age group, 0.5-8.9 uIU/ml for 55-87 years age group.

The study was conducted according to the criteria set by the declaration of Helsinki, and ethical approval was waived by the institutional review board due to the retrospective nature of the study. Data were analyzed by using the statistical package for social sciences (SPSS version 25.0). Data were presented as either mean and standard deviation for quantitative and frequency, relative percentages for categorical variables. The student's t-test was applied for quantitative measurements, while Pearson's correlation coefficients were applied for linear relationships. The receiver operating characteristic curve was used to obtain optimum cut-off for laboratory parameters predicting disease severity. The values were reported as the area under the curve (AUC), standard error (SE), sensitivity, specificity, positive predictive value, and negative predictive value.

Kaplan-Meier survival curve was deployed for those parameters and factors compared with log-rank (Mantel-Cox) test.

Our analysis of 54 COVID-19 patients had a mean age of 53.29 ± 15.59 years, with the majority of them being females (61%). There was a major difference in serum TSH observed among severe/critical COVID-19 patients (p < 0.001). As a result, inferential statistics were used to assess the relationship between serum TSH and disease incidence and other biochemical markers (Table 1) . T3 and T4 levels in the blood were not found to be linked to disease severity. Low serum TSH (<0.996 uIU/ml) was found to be statistically significant with disease severity (mean:

1.14 ± 0.35, p < 0.001). Cox proportional hazard model showed a significantly higher risk of disease severity with low TSH levels (hazard ratio: 

Our patients who appear to have the euthyroid sick syndrome exhibited severe COVID-19 manifestations; the specific clinical relevance of a low TSH is unclear. However, a euthyroid sick syndrome in severe COVID-19 patients was previously discussed in a few studies. 4, 5 The vast majority of hospitalized patients with critical illness are known to undergo transient thyroid hormone dysregulations, 6, 7 which are termed as nonthyroidal illness syndrome or thyroid allostasis in critical illness, tumors, uremia, and starvation (TACITUS). 8 The probable molecular mechanisms responsible are oxidative stress causing inflammatory mediators release leading to upregulation of thyroid hormones and feedback mechanisms. 9 There were a few limitations of our study, a single-center analysis with limited sample size, and no study groups were defined on the basis of thyroid status. An approach of comparing severity among those having normal thyroid function versus those with deranged T A B L E 1 Baseline data and major outcomes of the study population (n = 54) 

It is wise on the part of the healthcare providers to adopt a cautious approach when treating COVID-19 patients with altered thyroid levels as they can predict disease severity and correlate with biomarkers.

The authors declare that there are no conflict of interests. 

Ethical approval was waived in this study from the institutional review board, and consent to participate was not required due to the retrospective nature of data collection. 

Any datasets will be made available upon reasonable request from the corresponding author.

F I G U R E 2 Kaplan-Meier curve of survival function with TSH < 0.996 uIU/ml giving a statistically significant difference of p < 0.001. TSH, thyroid-stimulating hormone 

COVID-19 pandemic -Wikipedia

Endocrine involvement in COVID-19: mechanisms, clinical features, and implications for care

Thyroid complications of SARS and coronavirus disease 2019 (COVID-19)

Thyroid function analysis in COVID-19: a retrospective study from a single center

Euthyroid sick syndrome in patients with COVID-19

Beyond low plasma T3: local thyroid hormone metabolism during inflammation and infection

Non-thyroidal illness in the ICU: a syndrome with different faces

Thyroid allostasisadaptive responses of thyrotropic feedback control to conditions of strain, stress, and developmental programming

TSH and thyrotropic agonists: key actors in thyroid homeostasis

Subacute thyroiditis after Sars-COV-2 infection